サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：神経の修復と再生の世界市場-2023年～2030年
市場調査レポート
商品コード
1373366

神経の修復と再生の世界市場-2023年～2030年

Global Nerve Repair and Regeneration Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
神経の修復と再生の世界市場-2023年～2030年
出版日: 2023年10月18日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

神経修復は組織工学の一分野であり、細胞外マトリックスを模倣した人工神経を移植し、神経の再生を強化することを目的としています。神経修復・再生手術は、神経損傷によって部分的または完全に失われた機能や感覚を回復させることを目的としています。

神経導管やラップは、末梢神経損傷に対する包帯となり、神経環境を保護します。神経修復のための一般的な手術には、幹細胞治療、直接神経修復、神経移植などがあります。

市場力学

神経刺激システムへの投資の増加

神経刺激装置は、外科医が患者により的を絞った効果的な治療を提供できるようにすることで、神経疾患の診断と管理に重要な役割を果たしています。主要企業からの大規模な投資は市場の成長を後押しし、企業からのこうした効果的な資金は、研究発見を神経疾患の新たな診断や治療法に変えるのに役立っています。

例えば、2023年4月、Saluda Medical Inc.は、新たな投資家であるWellington Managementが主導する1億5,000万米ドルのエクイティファイナンスラウンドの調達を宣言しました。この資金調達による純収入は、Evoke脊髄シミュレーション（SCS）システムの商業リリースを進めるために使用されます。

さらに2022年2月、ナル・メディカルは1億400万米ドルのエクイティファイナンスを実施しました。このラウンドは新たな投資家であるMVMパートナーズとギルデヘルスケアが主導し、FDAが脊髄刺激（SCS）と末梢神経刺激（PNS）の適応を認めたNalu神経刺激システムにPura Vida Investmentsが参加しました。

また、SPRセラピューティクスは2021年10月、FDA承認のSPRINT末梢神経刺激システムの商業的普及を加速させるため、シリーズD成長株融資で3,700万米ドルをオーバーサブスクライブで調達しました。

さらに、世界の神経修復・再生市場は、神経損傷や神経疾患の有病率の上昇、技術の進歩、低侵襲手術の増加など、さまざまな要因によって牽引されており、予測期間における市場の牽引役となることが期待されています。

神経刺激の高コスト

神経刺激デバイスの高コスト、政府機関による厳しい規制、神経刺激デバイスのコンプライアンス基準は、予測期間中に市場が阻害されると予想される要因です。例えば、米国では、脳深部刺激手術の費用は、移植装置、入院費、麻酔を含めて35,000ドルから100,000ドルに及ぶ。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 神経刺激システムへの投資の増加
      • 抑制要因
    • 抑制要因
      • 神経刺激のコストが高い
      • YY
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • DMI意見

第6章 COVID-19分析

第7章 製品タイプ別

  • 神経刺激および神経調節デバイス
    • 脊髄刺激装置
    • 脳深部刺激装置
    • 仙骨神経刺激装置
    • 迷走神経刺激装置
    • 胃電気刺激装置
  • 生体材料
    • 神経導管
    • 神経ラップ
    • 神経グラフト
    • その他

第8章 手術タイプ別

  • 幹細胞治療
  • 直接神経修復
  • 神経移植
  • その他

第9章 エンドユーザー別

  • 病院
  • 神経センター
  • 外来手術センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Medtronic Plc
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Cirtec Medical
  • Synapse Biomedical Inc.
  • Renishaw Plc.
  • Orthomed LLC
  • AxoGen Inc
  • Integra LifeSciences
  • LinaNova Plc.

第13章 付録

目次
Product Code: MD1624

Overview

Nerve repair is a field of tissue engineering that aims to graft artificial nerves that could imitate the extracellular matrix and reinforce nerve regeneration. Nerve repair and regeneration surgery aims to restore function and sensation that was partially or completely lost due to nerve damage.

Nerve conduits and wraps provide an encasement for peripheral nerve injuries and protection of the neural environment. Commonly performed surgery for nerve repair includes stem cell therapy, direct nerve repair, and nerve grafting.

Market Dynamics

Increasing investments in nerve stimulation systems

Neurostimulation devices play a crucial role in diagnosing and managing neurological conditions by allowing surgeons to provide more targeted and effective care to patients. The major investments from key companies help to drive market growth and these effective funds from companies help to transform research discoveries into new diagnoses and treatments for neurological diseases.

For instance, in April 2023, Saluda Medical Inc. declared the raise of a $150 million equity financing round led by new investor Wellington Management. The net proceeds from the financing are used to advance the commercial release of the Evoke Spinal Cord Simulation (SCS) System.

Additionally, in February 2022, Nalu Medical raised $104M in Equity Financing. The round was led by new investors MVM Partners and Gilde Healthcare with participation from Pura Vida Investments for the Nalu Neurostimulation System which is FDA-cleared for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications.

Also, in October 2021, SPR Therapeutics raised $37 million in oversubscribed Series D growth equity financing to accelerate the rapidly growing commercial uptake of its FDA-cleared SPRINT Peripheral Nerve Stimulation System.

Furthermore, the global nerve repair and regeneration market is driven by various factors like the rising prevalence of nerve injuries and neurological diseases, technological advancements, and a rise in minimally invasive surgeries are expected to drive the market in the forecast period.

The high cost of nerve stimulation

The high cost of neurology devices, strict regulations by the government bodies, and compliance standards of the neurology stimulation devices are the factors the market is expected to get hampered in the forecast period. For instance, in the United States, the cost of deep brain stimulation surgery including the implanted device, hospital fees, and anesthesia can range from $35,000 to $100,000.

Segment Analysis

The global nerve repair and regeneration market is segmented based on product type, surgery type, end users and region.

Neurostimulation and Neuromodulation Devices accounted for approximately 39.8% of the market share

Neurostimulation devices utilize a battery and electrodes to provide electrical or magnetic forces through the scalp to certain regions of the brain. Neurostimulation and neuromodulation devices are expected to hold the largest market share over the period forecast owing to increasing new standard nerve stimulator launches and technological advancements.

For instance, in January 2023, Abbott Laboratories launched the world's smallest implantable, rechargeable spinal cord stimulation system for chronic pain. This stimulation system is clinically proven to reduce pain and improve people's ability to perform everyday activities.

Additionally, in February 2023, LivaNova launched SenTiva Duo, an implantable pulse generator that provides vagus nerve stimulation therapy for patients with drug-resistant epilepsy.

Geographical Analysis

North America is expected to hold a significant position in the global nerve repair and regeneration market share

The global nerve repair and regeneration market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising prevalence of neurological disorders, and product launches, this trend is anticipated to continue throughout the forecast period.

For instance, an estimated 6.7 million Americans aged 65 and over are predicted to have Alzheimer's dementia in 2023, and this number may increase to 13.8 million by 2060, according to a report released by the Alzheimer's Association in March 2022. Hence, the usage of nerve stimulation devices increases in treating Alzheimer's patients.

Additionally, in September 2023, launched its Axoguard HA+ Nerve Protector. It is a revolutionary peripheral nerve injury protection device that is specially crafted to offer both short- and long-term protection.

COVID-19 Impact Analysis:

The COVID-19 pandemic has had a significant impact on the global nerve repair and regeneration market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, device launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the nerve repair and regeneration market is expected to be moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include: Medtronic Plc., Abbott Laboratories, Boston Scientific Corporation, Cirtec Medical, Synapse Biomedical Inc., Renishaw Plc., Orthomed LLC, AxoGen Inc., Integra LifeSciences LinaNova Plc. Among others.

Key Developments

  • In February 2023, ANEUVO, initiated a clinical study of the ExaStim TSS system, a wirelessly-controlled neuromodulation system designed to deliver transcutaneous spinal cord stimulation (TSS).
  • In March 2022 Integra LifeSciences Holding Corporation introduced NeuraGen 3D Nerve Guide Matrix which is a resorbable implant for the repair of peripheral nerve discontinuities.

Why Purchase the Report?

  • To visualize the global nerve repair and regeneration market segmentation based on product type, surgery type, end users and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of nerve repair and regeneration market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global nerve repair and regeneration market report would provide approximately 61 tables, 58 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Surgery Type
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Market Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing investments in nerve stimulation systems
      • 4.1.1.2.
    • 4.1.2. Restraints
      • 4.1.2.1. The high cost of nerve stimulation
      • 4.1.2.2.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Neurostimulation and Neuromodulation Devices *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Spinal Cord Stimulation Devices
    • 7.2.4. Deep Brain Stimulation Devices
    • 7.2.5. Sacral Nerve Stimulation Devices
    • 7.2.6. Vagus Nerve Stimulation Devices
    • 7.2.7. Gastric Electric Stimulation Devices
  • 7.3. Biomaterial
    • 7.3.1. Nerve Conduit
    • 7.3.2. Nerve Wrap
    • 7.3.3. Nerve Graft
    • 7.3.4. Others

8. By Surgery Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
    • 8.1.2. Market Attractiveness Index, By Surgery Type
  • 8.2. Stem cell therapy *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Direct Nerve Repair
  • 8.4. Nerve grafting
  • 8.5. Others

9. By End Users

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 9.1.2. Market Attractiveness Index, By End Users
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Neuro Centers
  • 9.4. Ambulatory Surgical Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Medtronic Plc
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Abbott Laboratories
  • 12.3. Boston Scientific Corporation
  • 12.4. Cirtec Medical
  • 12.5. Synapse Biomedical Inc.
  • 12.6. Renishaw Plc.
  • 12.7. Orthomed LLC
  • 12.8. AxoGen Inc
  • 12.9. Integra LifeSciences
  • 12.10. LinaNova Plc.

LIST NOT EXHAUSTIVE.

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us